Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Cancer
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the...
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful...
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated...
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half...
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including...
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 millionSOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial...
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Advancement across Company’s pipeline towards regulatory and data milestonesBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA,...
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc....
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid...
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - -...
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and...
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity Psilocybin Packaging...
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines,...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second...
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million...
